HIV can develop resistance to blockbuster antiviral lenacapavir—but at a cost to the virus

Long-acting antiviral medications are transforming HIV prevention and care, requiring only minimalistic dosing. But as the use of lenacapavir expands, scientists are probing a critical question: If ...
UNAIDS

Review and mapping of Global Fund investments in priority comorbidities in Grant Cycle 7 to improve the health and well-being of people living with or at risk of HIV and/or TB

This report developed by UNAIDS and the United for Global Mental Health reviews and maps Global Fund investments in priority HIV and TB comorbidities in Grant Cycle 7 (GC7), including key ...